Kyowa Kirin Co. Ltd. (4151.TO) Tokyo Half-Year Ended June 30 GROUP 2025 2024 Revenue Y230.65 bln Y232.97 bln Pretax Profit Y21.98 bln Y46.52 bln Net Profit Y16.32 bln Y37.78 bln Per share Earnings Y31 ...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with ...

Consumers are increasingly prioritizing long-term health and focusing on prevention over cure with beverages acting as a ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

A campaign backed by Kyowa Kirin, Amgen and Sanofi is calling on prominent organizations with medical websites to bring their ...

The global preeclampsia drug market is poised for significant growth due to increasing awareness, advancements in diagnostics, and a higher prevalence of hypertension in pregnant women. Preeclampsia, ...

Under the terms of the co-promotion agreement, Kyowa Kirin US will have the right and responsibility to co-promote ziftomenib for up to a specified percentage of promotional activities in the US.